TrialPath
Recruiting

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

NCT06959615 · Jacobio Pharmaceuticals Co., Ltd.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
About this study
Study JAB-23E73-1001 is a global multicenter, open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anticancer activity of JAB-23E73 as a single agent in adult patients with advanced solid tumors with KRAS alteration. This study consists of a Phase 1a dose-escalation, followed by Phase 1b dose-expansion (dose optimization) and Phase 2a indication expansion. After completing dose-escalation, the MTD or preliminary RP2D of JAB-23E73 will be determined. Then, two of the alternative dosages of JAB-23E73 will be selected to further evaluate the efficacy, safety and PK in patients with KRAS-alternated NSCLC or other tumors, and patients may be further selected by certain/several types of KRAS-alternations based on dose escalation data. The RP2D will be determined according to the safety, efficacy and PK data from phase 1b.
Eligibility criteria
Inclusion Criteria: 1. Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer with evidence of KRAS gene alteration (including gene mutation and wild type amplification). 2. Able to provide an archived tumor tissue sample or fresh biopsy sample. 3. Life expectancy ≥3 months at the start of treatment. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. ≥1 measurable lesion per RECIST v1.1. 6. Adequate organ function. Exclusion Criteria: 1. Unable to swallow oral medications or with gastrointestinal dysfunction or gastrointestinal disease that significantly alters the absorption of medication. 2. Previous treatment with rat sarcoma (RAS) targeting agents. 3. Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases. 4. Impaired cardiovascular function or clinically significant cardiac disease. 5. Mean QT interval corrected using Fridericia's formula (QTcF) \>470 msec. 6. Females who are pregnant or breastfeeding.
Study design
Enrollment target: 334 participants
Allocation: non_randomized
Masking: none
Age groups: child, adult, older_adult
Timeline
Starts: 2024-11-22
Estimated completion: 2027-08-31
Last updated: 2026-01-20
Interventions
Drug: JAB-23E73Drug: JAB-23E73
Primary outcomes
  • • Phase 1: Number of participants with dose limiting toxicities (DLT) (Up to 21 days)
  • • Phase 2a: Objective response rate (ORR) (Up to approximately 2 years)
Sponsor
Jacobio Pharmaceuticals Co., Ltd. · industry
Contacts & investigators
ContactJacobio Pharmaceuticals · contact · clinicaltrials@jacobiopharma.com · 86 10 56315466
All locations (32)
Anhui Provincial Cancer HospitalNot Yet Recruiting
Hefei, Anhui, China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting
Beijing, Beijing Municipality, China
Beijing Cancer HospitalRecruiting
Beijing, Beijing Municipality, China
Beijing Chest HospitalRecruiting
Beijing, Beijing Municipality, China
Peking Union Medical College HospitalRecruiting
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical UniversityNot Yet Recruiting
Beijing, Beijing Municipality, China
Fujian cancer HospitalNot Yet Recruiting
Fuzhou, Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityRecruiting
Guangzhou, Guangdong, China
Guangxi Medical University Cancer HospitalRecruiting
Nanning, Guangxi, China
National Cancer Center/Cancer Hospital- Langfang Campus, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting
Langfang, Hebei, China
Harbin Medical University Cancer HospitalRecruiting
Haerbin, Heilongjiang, China
Henan Cancer HospitalRecruiting
Zhengzhou, Henan, China
The First Affiliated hospital of Zhengzhou UniversityRecruiting
Zhengzhou, Henan, China
Tongji HospitalNot Yet Recruiting
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan UniversityRecruiting
Wuhan, Hubei, China
Hunan Cancer HospitalNot Yet Recruiting
Changsha, Hunan, China
Nanjing Drum Tower HospitalRecruiting
Nanjing, Jiangsu, China
Jiangsu Cancer HospitalNot Yet Recruiting
Nanjing, Jiangsu, China
Jiangsu Province HospitalRecruiting
Nanjing, Jiangsu, China
The First Affiliate of Soochow UniversityNot Yet Recruiting
Suzhou, Jiangsu, China
The First Affiliated hospital of Nanchang UniversityRecruiting
Nanchang, Jiangxi, China
The First Hospital of China Medical UniversityRecruiting
Shenyang, Liaoning, China
Shanghai Jiaotong University School of Medicine Ruijin HospitalNot Yet Recruiting
Shanghai, Shanghai Municipality, China
Fudan University Zhongshan HospitalNot Yet Recruiting
Shanghai, Shanghai Municipality, China
Huashan Hospital Fudan UniversityNot Yet Recruiting
Shanghai, Shanghai Municipality, China
ShanXi Cancer HospitalRecruiting
Taiyuan, Shanxi, China
The First Affiliated hospital of Xi'an Jiaotong UniversityNot Yet Recruiting
Xi’an, Shanxi, China
West China Hospital, Sichuan UniversityNot Yet Recruiting
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute&HospitalNot Yet Recruiting
Tianjin, Tianjin Municipality, China
Zhejiang Cancer HospitalRecruiting
Hangzhou, Zhejiang, China
The Second Affiliate Hospital Zhejiang University School of MedicineNot Yet Recruiting
Hangzhou, Zhejiang, China
Zhejiang Provincial People's HospitalNot Yet Recruiting
Hangzhou, Zhejiang, China
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration · TrialPath